Introduction
============

Graft failure (GF), estimated to occur in 1-5% of cases after myeloablative conditioning and in up to 30% of cases after reduced-intensity conditioning (RIC),^[@b1-1042314]^ still remains a relevant cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT).^[@b2-1042314]^ Despite a slight reduction of its incidence over the last decade, mortality after GF remains as high as 11%.^[@b3-1042314]^ To date, in the absence of effective treatment options, re-transplantation, from either the same, or whenever possible, a different donor is considered the treatment of choice.^[@b2-1042314]^ Currently identified risk factors for GF include: i) human leukocyte antigen (HLA)-disparity and sex mismatch in the donor/recipient pair; ii) presence of donor-specific antibodies (DSA) in the recipient; iii) T-cell depletion (TCD) of the graft; iv) ABO-blood group mismatch; v) use of RIC; vi) a diagnosis of non-malignant disorders (in particular thalassemia, severe aplastic anemia, SAA, and hemophagocytic lymphohistiocytosis, HLH); vii) viral infections; viii) low nucleated cell dose in the graft; and ix) the use of myelotoxic drugs in the post-transplant period.^[@b1-1042314]--[@b4-1042314]^

In the last two decades, several groups have investigated immune-mediated GF. In particular, it has been shown that immune-mediated GF is mainly caused by host T and natural killer (NK) cells surviving the conditioning regimen, through a classical alloreactive immune response against non-shared, major (in case of HLA-partially-matched HSCT) or minor (in case of fully HLA-matched HSCT) histocompatibility antigens.^[@b2-1042314],[@b5-1042314],[@b6-1042314]^ However, to date the molecular pathways involved in immune-mediated GF have not yet been completely clarified. Indeed, since the inhibition of different pathways (including perforin-FasL^−^, TNFR-1^−^, and TRAIL-dependent cytotoxicity) did not prove to be efficient in preventing GF, the pathophysiological mechanisms responsible for GF seem to be multiple and likely to be redundant.^[@b7-1042314]^ Nonetheless, consistently over the years, different groups have suggested a pivotal pathogenic role of IFNγ in GF pathophysiology,^[@b8-1042314]--[@b14-1042314]^ through both direct \[e.g. inhibition of hematopoietic stem cell (HSC) self-renewal, proliferative capacity, and multilineage differentiation\]^[@b10-1042314],[@b11-1042314]^ and indirect (e.g. induction of FAS expression on HSC, with increased apoptosis in the presence of activated cytotoxic T cells)^[@b8-1042314],[@b12-1042314]^ effects.

Despite these experimental data, there has still not been any *in vivo* characterization of GF in humans. Indeed, although the expansion of host CD8^+^ T cells in patients experiencing GF has been previously demonstrated *in vivo*,^[@b15-1042314],[@b16-1042314]^ a more detailed characterization of this cell population is lacking. Thus, we started a prospective study aimed at better characterizing the pathophysiology of GF, focusing on the identification of biological markers that: (i) could predict early the occurrence of GF in the clinical setting; and (ii) could be used as a therapeutic target with clinically available biological agents. For this purpose, we broadly investigated cytokine and chemokine levels in peripheral blood (PB), as well as the cellular features in bone marrow (BM) biopsies of patients experiencing this complication. After confirming *in vivo* a role of IFNγ-pathway in the development of GF, we also investigated in an animal model of GF whether the sole inhibition of IFNγ would be able to prevent/treat GF. Finally, in view of these findings and the similarity between immune-mediated GF and HLH, we treated, in compassionate use (CU), with emapalumab, an anti-IFNγ monoclonal antibody recently approved for the treatment of HLH,^[@b17-1042314]^ three patients with primary HLH, who, after having experienced GF, underwent a second HSCT.

Methods
=======

Patients
--------

Patients aged from 0.3 to 21 years, who received an allograft from any type of donor/stem cell source between January 1^st^ 2016 and August 31^st^ 2017 at the IRCCS Bambino Gesù Children's Hospital in Rome, Italy, were considered eligible for the study. All patients or legal guardians provided written informed consent, and the entire research was conducted under institutional review board approved protocols and in accordance with the Declaration of Helsinki. The Bambino Gesù Children's Hospital Institutional Review Board approved the study.

Cytokine profile
----------------

In order to identify a cytokine/chemokine profile predictive of GF, PB samples were collected at different time points after HSCT: day 0, +3±2, +7±2, +10±2, +14±2, +30±2 after transplantation. Validated MesoScale Discovery (MSD, Rockville, MD, USA) platform-based immunoassay was used for the quantification of IFNγ, sIL2Rα, CXCL9, CXCL10, TNFα, IL6, IL10, and sCD163 serum levels.

Bone marrow biopsy: histopathology analysis and immunofluorescence
------------------------------------------------------------------

Bone marrow biopsies were obtained when GF was suspected. (Since BM characterization was a secondary end point of this study and BM aspiration is not routinely performed in this condition, parents/legal guardians could refuse the procedure.) Details on BM specimen preparation, histopathology analysis and immunofluorescence are reported in the *Online Supplementary Appendix.*

Immune-phenotypic analysis
--------------------------

The following monoclonal antibodies (mAbs) were used: anti-CD3, CD4, CD8, CD25, CD27, CD28, CD45RA, CD45RO, CD56, CD57, CD62L, CD95, CD127, CD137, CD197, CD223 (Lag3), CD279 (PD1), and CD366 (TIM3) (BD Biosciences, NJ, Biolegend, CA and Affymetrix, CA, USA).

*In vivo* murine model of hematopoietic stem cell transplantation rejection
---------------------------------------------------------------------------

C57BL/6 Ifngr1^−/−^ mice were used as recipient, while C57BL/6 Ifngr1^+/+^ were used as donor. All animal experiments were performed in accordance with the Swiss animal protection law. Details on experiments are reported in the *Online Supplementary Appendix.*

Emapalumab administration in compassionate use to hemophagocytic lymphohistiocytosis patients experiencing graft failure
------------------------------------------------------------------------------------------------------------------------

Emapalumab (previously known as NI-0501), a fully human anti-IFNγ monoclonal antibody, was administered on a CU basis (after local ethical committee approval) to three patients affected by HLH who experienced GF after a first TCD HSCT from a partially-matched family donor (PMFD) with the aim of preventing flares of HLH and a second GF. The drug was administered by 1-hour intravenous infusion twice a week until sustained donor engraftment or GF. The dose varied between 1 and 6 mg/kg, based on pharmacokinetic data.

Additional methods are presented in the *Online Supplementary Appendix*.

Statistical analysis
--------------------

Unless otherwise specified, quantitative variables were reported as Mean±Standard Error of Mean (SEM); categorical variables were expressed as absolute value and percentage. Clinical characteristics of patients were compared using the χ^2^ test or Fisher exact test for categorical variables, while the Mann-Whitney rank sum test or the Student *t*-test (two-sided) was used for continuous variables, as appropriate. For multiple comparison analyses, statistical significance was evaluated by a repeated measure ANOVA test, followed by a Log-rank (Mantel-Cox) test for multiple comparisons.

Results
=======

Patients' characteristics
-------------------------

During the study period, 15 consecutive patients who experienced GF were eligible for the study. Most of them were affected by non-malignant disorders characterized by a high risk of GF (e.g. SAA and HLH) and received a TCD allograft from a PMFD. Fifteen children, matched for transplant characteristics, who had sustained donor engraftment during the same period were used as controls. Patients' and control characteristics are detailed in [Table 1](#t1-1042314){ref-type="table"}. Main transplant characteristics (i.e. conditioning regimen, type of donor, graft manipulation) were comparable between the two groups (except for a trend for a lower age in the GF group). Of the 15 patients experiencing GF, ten were tested for anti-HLA antibodies, which were detected in five patients (50%). Those who had a mean fluorescence intensity (MFI) of anti-HLA antibodies \>5000 received rituximab and underwent plasma-exchange to lower the value below the threshold of 5000 MFI;^[@b18-1042314]^ this treatment successfully reduced the MFI value in all cases.

###### 

Characteristics of patients who either did or did not experience graft failure (GF).

![](1042314.tab1)

Signs and symptoms of patients who either did or did not experience GF are detailed in [Table 2](#t2-1042314){ref-type="table"}. The most frequent sign associated with GF was fever, occurring at a median time of six days from the infusion of the graft (range 1-16 days). Moreover, both lactate dehydrogenase (LDH) and ferritin increased in many patients (80% and 46.7%, respectively); these laboratory findings appeared late after HSCT (at a median of 11 and 10 days, respectively). All patients received steroids in an attempt to avoid GF, without benefit. Chimerism analysis performed on PB showed only recipient cells in all GF cases, while in all controls but one, who showed mixed chimerism, only donor-origin cells were found.

###### 

Signs and symptoms of patients who experienced graft failure (GF).

![](1042314.tab2)

Cytokine/chemokine profile
--------------------------

Kinetics of IFNγ, CXCL9, IL10 and IL2Rα serum levels are shown in [Figure 1A-D](#f1-1042314){ref-type="fig"}, while serum levels of TNFα, CXCL10, sCD163 and IL6 are shown in [Figure 2A-D](#f2-1042314){ref-type="fig"}. Serum levels of these cytokines/chemokines differed between patients experiencing GF and controls, starting from the first days after the infusion of the graft. Notably, for IFNγ, CXCL9, IL10 and TNFα, this difference became statistically significant already at day +3 after HSCT. In particular, mean IFNγ levels at day +3 were 8859±7502 pg/mL in GF patients *versus* 0 pg/mL in controls (*P*=0.03); CXCL9 levels were 1514.0±773 pg/ml *versus* 233.6±50.1 pg/mL (*P*=0.0006); IL10 levels were 58.8±39.1 pg/mL *versus* 1.7±1.1 pg/mL (P=0.01); TNFα levels were 3.5±1.0 pg/mL *versus* 0.9±0.2 pg/mL (*P*=0.02). In this cohort, receiver operating characteristics (ROC) analysis on CXCL9 levels at day +3 showed an area under the curve (AUC) of 0.905 \[95% Confidence Interval (CI) 0.709-0.987; *P*\<0.0001\] (*Online Supplementary Figure S1*); a cut-off value of 274.5 pg/mL had a sensitivity of 88.89% and a specificity of 78.57%. The ROC analysis of other markers, which were significantly increased at day +3 showed an AUC of 0.802 for TNFα (95%CI: 0.566-0.944; *P*=0.006), of 0.756 for IL10 (95%CI: 0.529-0.912; *P*=0.011) and of 0.682 for IFNγ (95%CI: 0.471-0.849; *P*=0.017).

![Cytokine/chemokine profile. Serum levels of interferon (IFN)-γ (A), CXCL9 (B), CXCL10 (C), and sIL2Rα (D) in patients who either did (red line) or did not (blue line) experience graft failure (GF). All graphs represent Mean and Standard Error of Mean for each variable. HSCT: hematopoietic stem cell transplantation.](1042314.fig1){#f1-1042314}

![Cytokine/chemokine profile. Serum levels of TNFα (A), CXCL10 (B), sCD163 (C), IL6 (panel D). Red line: patients who experience graft failure (GF); blue line: controls. All graphs represent Mean and Standard Error of Mean for each variable. HSCT: hematopoietic stem cell transplantation.](1042314.fig2){#f2-1042314}

Since primary HLH patients commonly present increased IFNγ and its related chemokines serum levels during disease reactivation/flare (that is frequent after failure of HSCT^[@b19-1042314]^), we performed additional analyses excluding this subset of patients in order to validate the data in disorders other than HLH. Even after excluding HLH patients, CXCL9 and IL10 serum levels remained significantly higher in patients experiencing GF in comparison with controls (*Online Supplementary Figure S2*).

Activation of macrophages and T lymphocytes characterizes graft failure in allogeneic hematopoietic stem cell transplantation
-----------------------------------------------------------------------------------------------------------------------------

Bone marrow biopsies were obtained at time of GF in seven patients and were compared to those of five controls (obtained in a similar time period, i.e. between 2 and 3 weeks after HSCT). In all GF patients, evaluation of BM morphology showed different stages of GF with reduced cellularity ([Figure 3A](#f3-1042314){ref-type="fig"} and *Online Supplementary Figure S3A and B*) as compared to patients with sustained donor engraftment (*Online Supplementary Figure S4A*). In GF patients, the percentage of myelocytes and erythroid precursors was reduced compared to controls ([Figure 3B](#f3-1042314){ref-type="fig"}). Erythroid colonies were markedly smaller, with a higher percentage of premature erythroid cells. The megakaryocytic lineage was well represented in all GF cases, but with irregular distribution ([Figure 3C](#f3-1042314){ref-type="fig"}). In several areas of the specimens, a remarkable number of apoptotic cells partially grouped in clusters was observed ([Figure 3D](#f3-1042314){ref-type="fig"}). All biopsies showed stromal damage resulting in edema ([Figure 3E](#f3-1042314){ref-type="fig"}). While the total number of CD68^+^ macrophages was comparable between GF patients and controls ([Figure 4A](#f4-1042314){ref-type="fig"}), significantly higher percentages of CD68^+^ and CD163^+^ macrophages, with cellular fragments, erythrocytes and lipid vacuoles in their cytoplasm, (indicating activation and phagocytic activity) ([Figure 3F and G](#f3-1042314){ref-type="fig"} and *Online Supplementary Figure S3C and D*), were observed in comparison to controls \[median 80% (range 30-100%) *vs.* 0% (range 0-5%); *P*\<0.0001\] ([Figure 4B](#f4-1042314){ref-type="fig"} and *Online Supplementary Figure S4B and C*). In all analyzed samples from GF patients, a significant increase in T lymphocytes ([Figures 3H](#f3-1042314){ref-type="fig"} and [4A](#f4-1042314){ref-type="fig"} and *Online Supplementary Figure S3G*), with a predominance of CD8^+^ cytotoxic T cells, expressing perforin, Granzyme B and TIA-1 ([Figures 3I and J](#f3-1042314){ref-type="fig"} and [4A](#f4-1042314){ref-type="fig"} and *Online Supplementary Figure S5*) was observed. The *Online Supplementary Appendix* provides further details.

![Immunohistochemistry evaluation of bone marrow (BM) specimens in a patient experiencing graft failure (Pt \#4). (A) Hematoxylin & eosin (H&E) staining of a BM specimen at 4X magnification. (B) Evaluation of erythroid colony spreading by glycophorin staining (10X). (C) Megakaryocyte distribution evaluated by CD61 expression (10X). (D) H&E staining at 40X showing apoptotic events. (E) H&E staining revealing stromal damage and edema development (40X). Characterization of the macrophage population by CD68 (F) and CD163 (G) staining (40X). Characterization and distribution of T lymphocytes by analysis of CD3 (H), CD4 (I), and CD8 (J) expression (10X).](1042314.fig3){#f3-1042314}

![Immunohistochemistry characterization of bone marrow (BM) in patients who either did or did not experience graft failure (GF). (A) Comparison of absolute number of CD3^+^, CD4^+^, CD8^+^, CD68^+^, TIA-1^+^, perforin^+^ and granzyme^+^ cells in BM of GF patients and controls (CTRL). The total number of positive cell for each marker was counted in five fields per sample under 20-fold magnification and reported as Mean±Standard Deviation. (B) Percentages of CD68^+^ cells with hemophagocytic activity (i.e. showing cellular fragments, erythrocytes and lipid vacuoles in their cytoplasm) in BM of GF patients and CTRL. ^\*^*P*\<0.05; ^\*\*^*P*\<0.01; ^\*\*\*^*P*\<0.001.](1042314.fig4){#f4-1042314}

Polyclonal T-cell pattern with predominant CD8 effector memory phenotype effector memory phenotype
--------------------------------------------------------------------------------------------------

In order to better characterize the role of T lymphocytes in GF, the TCR repertoire was initially analyzed in the CD3^+^ population, showing a polyclonal distribution of the Vβ chains (*Online Supplementary Figure S6*). Then, we extended our analysis on BM-infiltrating lymphocytes through flowcytometry in both controls and GF patients. Regarding NK (CD56^+^/CD3^−^) and γδ T cells (CD3^+^/CD4^−^/CD8^−^) no difference was observed between the two patient groups (*data not shown*). By contrast, in the αβ T-cell subset, the analysis revealed a significant difference in both CD4 (58.9%±13.4% *vs.* 7.6%±7.3%, controls *vs.* GF patients) and CD8 (25.9%±6.1% *vs.* 66.5%±18.2%, controls *vs.*GF patients) subsets (*P*\<0.0001 and *P*=0.0018, respectively) ([Figure 5A](#f5-1042314){ref-type="fig"}). We further characterized both CD4^+^ and CD8^+^ populations for the expression of memory markers. While no significant difference was detected in the CD4^+^ subpopulation, the CD8^+^ subset displayed a significant enrichment of effector memory T cells (EfM) (CD45RO^+^/CCR7-) (40.3±24.6% *vs.* 20.7%±7.3%, GF patients *vs.* CTRL patients; *P*=0.034) ([Figure 5B and C](#f5-1042314){ref-type="fig"}) and a significant reduction of the naïve subset (CD45RA^+^/CCR7^+^) (18.6%±16.6% *vs.* 28.6%±12.1%, GF patients *vs.* controls; *P*=0.014). See *Online Supplementary Appendix* for further details.

![Immuno-characterization of the T lymphocytes present in bone marrow aspirates of patients who either did or did not experience graft failure (GF). (A) Flow cytometry analysis of CD4^+^ and CD8^+^ population in patients with GF and controls (CTRL). Distribution of naïve (CD45RA^+^/CCR7^+^), central memory (CD45RO^+^/CCR7^+^), effector memory (CD45RO^+^/CCR7^−^), effector terminal (CD45RA^+^/CCR7^−^), and NK-T (CD3^+^/CD56^+^) subsets in CD4^+^ (B) or CD8^+^ (C) T cells. Activation and exhaustion profile in both the CD4^+^ and CD8^+^ population by the analysis of CD95 (D), CD127 (E), and CD57 (F). (A, D, E, and F) Each patient or CTRL is represented by a symbol and a horizontal line marks the median. (B and C) The average (+) and Median±Standard Deviation are shown. ^\*^*P*\<0.05; ^\*\*^*P*\<0.01; ^\*\*\*^*P*\<0.001; ^\*\*\*\*^*P*\<0.0001.](1042314.fig5){#f5-1042314}

Increasing expression of activation and exhaustion markers on T cells during graft failure
------------------------------------------------------------------------------------------

We evaluated the expression of several activation and exhaustion markers on infiltrating cells. As expected, in patients experiencing GF, both CD4^+^ and CD8^+^ cells displayed a significant activation profile, as demonstrated by the overexpression of CD95 (69.2%±23.0% *vs.* 93.9%±6.9% and 57.9%±27.2% *vs.* 98.35%±2.0%, controls *vs.* GF patients, respectively; *P*=0.021 and *P*=0.002) ([Figure 5D](#f5-1042314){ref-type="fig"}) and downregulation of CD127 (recently shown to be associated with prolonged T-cell receptor stimulation^[@b20-1042314]^) on the proliferating CD8^+^ cells (69.3%±16.9% *vs.* 37.9%±18.8%, controls *vs.* GF patients, respectively; *P*=0.014) ([Figure 5E](#f5-1042314){ref-type="fig"}). The expression of several exhaustion and senescence markers confirmed the status of prolonged activation of T lymphocytes located in the BM of GF patients, such as the upregulation of CD57 (CD57^+^: 10.2%±10.5% *vs.* 37.4%±12.4% and 34.7%±17.3% *vs.* 68.0%±18.8% controls *vs.* GF patients in CD4 and CD8 respectively; *P*=0.003 and *P*=0.011) ([Figure 5F](#f5-1042314){ref-type="fig"}). See *Online Supplementary Appendix* for further details.

Interferon-γ drives rejection of donor cells in Ifngr1^−/--^mice
----------------------------------------------------------------

In order to understand if the sole IFNγ-inhibition would be sufficient to prevent GF, we used an established mouse model of GF.^[@b13-1042314]^ As previously reported by Rottman *et al*.,^[@b13-1042314]^ the infection of Ifngr1^−/−^ mice with Bacillus Calmette-- Guérin (BCG) resulted in a rapid increase of circulating IFNγ levels reaching a concentration of 11,000 pg/mL on day 20 post-infection ([Figure 6A](#f6-1042314){ref-type="fig"}). HSCT performed at day 21, i.e. at the peak of IFNγ levels, resulted in poor chimerism as only 5% of the Ifngr1^+/+^ donor cells engrafted in the BCG-infected Ifngr1^−/−^ recipient mice. After day 21 post-BCG infection, serum IFNγ levels gradually decreased to a steady state level of approximately 100 pg/mL. This decrease in IFNγ serum levels correlated with an increase in chimerism as the Ifngr1^−/−^ recipient mice exhibited 19% HSC engraftment of donor cells at day 84 ([Figure 6A](#f6-1042314){ref-type="fig"}). For further assessing the role played by IFNγ in GF, BCG-infected Ifngr1^−/−^ recipient mice were given a neutralizing IFNγ mAb, XMG1.2, pre-and post-HSCT. Neutralization of IFNγ improved engraftment in BCG-infected Ifngr1^−/−^recipient mice because, at three months after the allograft, 45% of the lymphocytes were of donor origin (i.e. Ly5.1 positive), as compared to 19% in isotype control-treated mice ([Figure 6B](#f6-1042314){ref-type="fig"}). In order to assess IFNγ activity and ensure neutralization by XMG1.2, the IFNγ-dependent chemokine CXCL9 was measured. A decrease in CXCL9 serum levels during the XMG1.2 treatment was observed, confirming IFNγ neutralization in contrast to isotype control-treated mice ([Figure 6C](#f6-1042314){ref-type="fig"}). Once XMG1.2 treatment was interrupted, at day 42 post-BCG infection, a gradual increase in CXCL9 serum levels was observed, indicating restoration of IFNγ activity.

![Successful hematopoietic stem cell transplantation (HSCT) chimerism in interferon (IFN)-γR1^−/−^ mice correlates with low IFNγ activity; circulating CXCL9 levels is a biomarker of *in vivo* IFNγ activity. Ifngr1^−/−^ mice (expressing the Ly5.2 congenic marker) were intravenously (i.v.) infected with 1,106 CFU of Bacillus Calmette--Guérin (BCG) (strain Pasteur 1173P2). After 14, 20, 28, 35 and 42 days mice were treated i.v. with 100 mg/kg of an isotype control (n=5) or the anti-mIFNγ, XMG1.2 (n=5). At day 21, mice were infused with bone marrow from Ifngr^+/+^ mice, expressing the Ly5.1 marker, after mild irradiation (550 rads). Chimerism, assessed by determining the surface expression of Ly5.1 and Ly5.2 on lymphocytes, was analyzed by flow cytometry at different time points after HSCT treatment. IFNγ levels were quantified at different time points by ELISA using the Luminex technology. (A) Graph represents the super-imposition of the chimerism (black straight line) and the IFNγ levels (gray dotted line) in the isotype control treated mice. (B) Graph represents the chimerism determined in mice treated with the isotype control (black straight line) or with the XMG1.2 (gray straight line) mAbs. (C) Ifngr1^−/−^ mice were i.v. infected with 1.106 CFU of BCG (strain Pasteur 1173P2). After 14, 20, 28, 35 and 42 days mice were treated i.v. with 100 mg/kg of an isotype control (black straight line; n=5) or the anti-mIFNγ, XMG1.2 (gray straight line; n=5). At day 21, mice were transplanted with bone marrow from Ifngr^+/+^ mice, expressing the Ly5.1 marker, after mild irradiation (550 rads). At different time points post-BCG infection, circulating CXCL9 levels were quantified by ELISA using the Luminex technology. Ab: antibody.](1042314.fig6){#f6-1042314}

Emapalumab administration to patients after hematopoietic stem cell transplantation failure
-------------------------------------------------------------------------------------------

Three patients with primary HLH who experienced GF together with disease reactivation after a first TCD HSCT from a PMFD were treated with emapalumab both before and after the second HSCT (details are reported in *Online Supplementary Table S1*). For all these patients, the use of the other parent as a donor was not possible because of non-eligibility due to viral hepatitis. The CU of emapalumab was requested and obtained with the objective of controlling, without the use of myelosuppressive drugs other than those used in the conditioning regimen, HLH reactivation before and after a second HSCT. Emapalumab was administered at doses of 1-6 mg/kg every three days. Drug infusions were well tolerated and no significant safety event occurred. Two patients engrafted, while one rejected also the second HSCT without, however, experiencing a new HLH flare. This patient was successfully rescued with a third HSCT employing an unrelated cord blood (UCB) unit (notably, she received emapalumab until 3 days before UCB infusion). Remarkably, the two patients who engrafted upon treatment with emapalumab had very low levels of CXCL9 (i.e. below 102 pg/mL), indicating IFNγ neutralization, while this was not the case for the third patient at the time of the second transplant rejection. All these three patients are currently alive and disease-free, with a follow up of 24, 23 and 21 months, respectively.

Discussion
==========

Diagnosis and treatment of GF in HSCT recipients remain challenging. Indeed, sign and symptoms (e.g. fever, increase in LDH or ferritin serum levels) associated with this transplant complication are non-specific; moreover, re-transplantation, although associated with relevant risk of tissue-toxicity and infections, represents the treatment of choice, since steroids and other immunosuppressive drugs are usually ineffective for rescuing these patients.^[@b2-1042314]^ In this study, we investigated humoral and cellular features of GF occurring after allogeneic HSCT in children, documenting a pivotal role played by IFNγ in the pathophysiology of this complication. Apart from the indirect evidence provided by the observation of very high rates of primary and secondary rejection after HLA-identical HSCT in patients with IFNγ-receptor 1 deficiency,^[@b21-1042314]^ currently available clinical data about the role of IFNγ in GF in humans remain limited. Interestingly, we found that GF is characterized by the same clinical (including high-grade fever, hepato/splenomegaly, hemophagocytosis in BM)^[@b22-1042314],[@b23-1042314]^ and laboratory (i.e. increased ferritin, IFNγ, CXCL9, CXCL10, sCD163 and sIL-2Rα levels)^[@b24-1042314]--[@b28-1042314]^ features found in patients with HLH, where a central role of IFNγ has been shown.^[@b29-1042314]^

Our data indicate that IFNγ levels, and even more CXCL9 levels measured in PB, can predict GF with high sensitivity and specificity already at day +3 after graft infusion, while signs and symptoms of GF appear only later (see [Table 2](#t2-1042314){ref-type="table"}). Indeed, the current proposed risk score for GF determined on day +21 after HSCT, based on eight patient and transplant variables, showed good specificity, but low sensitivity.^[@b1-1042314]^ The high accuracy of CXCL9 in predicting GF, as indicated by the AUC of 0.905, renders this chemokine an ideal "candidate biomarker", as stated by the 2014 National Institutes of Health consensus on biomarkers.^[@b30-1042314],[@b31-1042314]^ CXCL9, also known as monokine induced by γ-interferon (MIG), is a chemokine specifically induced by IFNγ,^[@b32-1042314]^ and represent the most sensitive and specific of the soluble factors we analyzed. It binds to the chemokine receptor CXCL3 expressed on naïve T cells, Th1 CD4^+^ T cells, effector CD8^+^ T cells, as well as on NK and NKT cells, driving Th1 inflammation. Circulating CXCL9 levels have been shown to reflect the amount of IFNγ produced in organs, such as liver and spleen,^[@b25-1042314]^ which are the typical target of inflammation. This strong correlation with IFNγ produced in organs rather than in blood provides an explanation why, despite high CXCL9 serum levels, serum levels of IFNγ were found to be low or even undetectable in a few of our GF patients. Furthermore, elevated levels of CXCL9 have been related to graft rejection in solid organ transplantation (such as heart, kidney and lung transplantation),^[@b33-1042314]--[@b35-1042314]^ but, to the best of our knowledge, this is the first report demonstrating that the hyperproduction of IFNγ in GF occurring after HSCT results in increased CXCL9 serum levels. Among other cytokines/chemokines, we also observed increased levels of IL10, an important Th2 cytokine with anti-inflammatory properties, this finding being in agreement with the hyperproduction of this molecule recorded in patients with HLH.^[@b36-1042314]^

Our results are not only relevant for diagnostic purposes, but also suggest that IFNγ is a potential therapeutic target in GF. Indeed, independently of the mechanism of IFNγ-mediated GF (i.e. direct effect on HSC or HLH-like effect), our results support the investigation of IFNγ neutralization for prevention and/or treatment of GF in patients undergoing HSCT. The encouraging efficacy and safety data reported from the ongoing study in primary HLH with emapalumab (NI-0501), an anti-IFNγ monoclonal antibody,^[@b17-1042314],[@b37-1042314]^ provides additional support for the rationale for using this drug.^[@b38-1042314]^ The data we generated in the murine model of GF confirm and extend the role played by IFNγ previously demonstrated by Rottman *et al*.^[@b13-1042314]^ Moreover, we also show that the sole neutralization of IFNγ, without the administration of anti-IL12 (employed in the experiments reported by Rottman *et al*.),^[@b13-1042314]^ is able to improve engraftment. The observation that decreased CXCL9 production correlates with improved HSCT chimerism provides further support to a therapeutic intervention aimed at neutralizing IFNγ-pathway signaling. Finally, the data obtained in the three patients treated on a CU basis indicate that the use of an anti-IFNγ monoclonal antibody is safe also in a very fragile population, namely infants with a previous GF undergoing a second HSCT.

Four out of the seven patients we studied who underwent BM aspirate and biopsy showed evidence of hemophagocytosis. Indeed, it has been shown that an increased number of hemophagocytic macrophages in the BM obtained 14±7 days after HSCT is associated with higher risk of death due to GF.^[@b39-1042314]^ Moreover, in a cohort of adult patients receiving cord blood transplantation, GF was strictly related to the occurrence of HLH manifestations.^[@b23-1042314]^ Recently, in a retrospective study on peri-engraftment BM samples from 32 adult patients, Kawashima *et al*. proposed two histological measures, namely macrophage ratio and CD8^+^ ratio (defined as the ratio between the macrophage or CD8^+^ lymphocyte number on the total nucleated cell number), as predictors of GF at day +14.^[@b15-1042314]^

Despite some preliminary studies characterizing host T cell expansion in patients with GF,^[@b15-1042314],[@b16-1042314]^ no information is available regarding the phenotype of these cells. Our data indicate an active role of T lymphocytes in mediating GF. As previously reported,^[@b15-1042314]^ in these patients, the mononuclear infiltrate is mainly constituted by cytotoxic CD8^+^ lymphocytes with a predominant effector memory phenotype. This population was demonstrated to be activated, proliferating and cytotoxic, expressing specific molecules, such as Granzyme B, Perforin and TIA-1, involved in target-killing, as well as various activation and proliferation markers. Interestingly, we observed that CD8^+^ lymphocyte expansion is predominantly polyclonal, suggesting that the immune response is directed towards several antigens and not against few immunodominant epitopes. However, a significant enrichment of certain β clones was found. The cytopathic effect was clearly demonstrated by apoptotic cells surrounding proliferating T cells, which are long-term activated, as demonstrated by the expression of several exhaustion markers.^[@b40-1042314],[@b41-1042314]^ Furthermore, the remaining γ/d and CD4^+^ T-cell populations are similarly expressing exhaustion markers, underlying an over-stimulated environment. Notably, a particular behavior was observed in the NKT-cell population with a significant reduction of CD8^+^ NKT, probably due to their activation and a significant increase of CD4^+^ NKT. The role of these cells is yet to be fully elucidated, although they were shown to be able to prevent pancreatic islet transplant rejection, but also to sustain CD8^+^ T-cell expansion.^[@b42-1042314],[@b43-1042314]^ Given these data, a treatment able to interrupt the overproduction of molecules responsible for inflammation,^[@b33-1042314]^ such as an anti-IFNγ, could be beneficial in this setting.

Fifty percent of tested patients had anti-HLA antibodies: all those with positivity \>5,000 MFI received a desensitization therapy in order to lower the antibody title with the aim of reducing the risk of GF. Although we cannot exclude a role of anti-HLA antibodies in causing GF in our patients, all five positive patients showed increased values of IFNγ and/or related cytokines after HSCT. Thus, we can hypothesize that there may be a common final pathway and/or combined action (like that reported in solid organ transplantation)^[@b44-1042314]^ between humoral and cellular mechanisms sustaining GF.

Limitations of this study are the lack of a validation cohort and the relatively small number of patients included in the study. Another important limitation is that most patients experiencing GF that we report were transplanted from a PMFD after a TCD procedure (both being well-known risk factors for GF);^[@b2-1042314],[@b3-1042314]^ thus, our results should be further validated in other transplant settings, especially when post-transplant pharmacological graft-*versus*-host disease prophylaxis is used. Indeed, the use of calcineurin inhibitors or other immunosuppressive agents can modify IFNγ (and related cytokines) secretion kinetics.^[@b45-1042314]^

Overall, our data suggest that immune-mediated GF may share clinical and laboratory characteristics with HLH. Besides providing evidence for further investigating the use of markers to allow a non-invasive, prompt identification of patients at high risk of developing this severe complication of HSCT, the increased serum levels of IFNγ and CXCL9 found in GF patients provide a rationale for investigating a targeted therapy (i.e. anti-IFNγ therapy) in this complication. We are currently designing a clinical trial on the use of emapalumab for prevention and/or treatment of GF in patients at high risk of developing this complication.
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